Navigation Links
Tackling Atrial Fibrillation and Associated Cardiovascular Risk
Date:11/4/2008

- RecordAF Registry Baseline Data and New Data from the Landmark ATHENA

Study
PARIS, Nov. 4 /PRNewswire/ --

Live Webcast Media Briefing - non-US media only

Wednesday 12 November 2008 - 14.00-15.00am CET

Background:

-- AF is a growing health concern directly responsible for increased

morbidity and mortality

-- There is a need for a global prospective database like RecordAF, which

takes a closer look at disease characteristics and how management of AF

affects cardiovascular (CV) outcomes

-- AF is associated with a high hospitalization burden - 70 percent of AF

management costs are driven by hospitalization costs (Ringborg et al.

Europace 2008; 10:403-11)

-- A further sub-analysis of the ATHENA trial was conducted:

-- to better understand the impact of dronedarone on hospitalization

of AF patients particularly on the number and duration of CV and

non CV hospitalization nights

-- An additional sub-analysis was also conducted to further explore

dronedarone's rhythm and rate controlling properties

-- The ATHENA study is the first AF trial designed to evaluate the effect

of an anti arrhythmic drug (AAD) on morbidity and mortality. It showed

that dronedarone (brand name Multaq(R)), a new AAD undergoing the

registration process, can significantly improve CV outcomes including

reducing the risk of hospitalization and death.

Register on-line in advance of the online event:

1. Go to https://sanofiaventismediabriefing.webex.com/sanofiaventismediabriefing/ons t age/g.php?d=702842657&t=a&EA=nburns%40webex.com&ET=6b1f2c181b8fa5176928ed1c 72 009c4d&ETR=8789fb6f20765cb360e4d0c88cea0f23 (due to the length of this URL, please copy and paste it into your browser)

2. Click "Register"

3. On the registration form, enter your information then click "Submit"

Once the host approves your registration, you will receive a confirmation email containing instructions on how to join the event (event number and password) on the day of the announcement.

Once logged on, you will also be required to connect to a teleconference in order to participate in the live Q&A session with panelists at the end of the event.

Teleconference dial in number (toll-free):

1) To obtain your teleconference number, register first by following the instructions above.

2) Once connected, a pop-up window will appear

3) Select country of affiliation to obtain local dial-in number

4) Dial-in and enter your login details using the provided number within the pop-up window

Please ensure you log on to the event 15 minutes before the start time so as not to miss valuable information.

IMPORTANT NOTICE:

This event is not part of the official Scientific Sessions 2008 as planned by the AHA Committee on Scientific Sessions Programming


'/>"/>
SOURCE Sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Texas Cardiac Arrhythmia Institute at St. Davids Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation
2. Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
3. Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
4. Catheter Ablation System for Atrial Fibrillation Shows Reduced Procedure Time, Remarkable Safety Profile and Excellent Outcomes in Two Clinical Studies
5. American Heart Journals Publishes Results From ERATO Trial Showing Dronedarone (Multaq(R)) Improves Ventricular Rate Control in Patients With Permanent Atrial Fibrillation
6. Multaq(R) (dronedarone) Granted FDA Priority Review for Patients with Atrial Fibrillation
7. Studies of an Innovative Catheter Ablation System for Atrial Fibrillation Reveal Excellent Outcomes, Safety Profile and Fast Procedure Times
8. Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
9. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
10. ATS Medical Announces Initial Clinical Results of Stand-Alone Atrial Fibrillation Procedures Using ATS CryoMaze Product Line
11. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... -- VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported today ... to build a strong and stable market for trading ... the OTC Markets-pink current trading platform. Explains ... seeing an anomaly in market trading activities that may ... Company, but shareholders and market players as well. I ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
Breaking Medicine News(10 mins):